公司概述
Actuate Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company dedicated to developing therapies for the treatment of various cancers within the United States market. The firm functions within the healthcare sector, specifically targeting the biotechnology industry, which implies a focus on research-intensive development and regulatory compliance for novel drug candidates. As of the latest available data, the company possesses a market capitalization of $44.82 million and employs 12 individuals to execute its strategic initiatives. The current market cap combined with the absence of reported annual revenue indicates that Actuate is an early-stage enterprise where value is derived primarily from intellectual property and pipeline potential rather than established commercial earnings, reflecting a high-risk, high-reward position typical of pre-commercial biotech entities.
财务健康
The company reported a net income of $-22,227,852 over the trailing twelve months, while revenue and EBITDA figures are not available due to the clinical-stage nature of the business. The significant gap between nominal revenue and substantial net losses reveals a cost structure heavily weighted toward research and development expenses, clinical trial costs, and general administrative overheads required to advance drug candidates like elragusib injection through Phase 2 trials. Free cash flow stands at $-11,038,870, indicating that the company is consuming cash reserves to fund its operations and development pipeline, which limits immediate financial flexibility but is standard for companies in the early development phase. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, which mathematically reflects the fact that the company has not yet generated sufficient commercial sales to produce positive gross or operating profitability. On the balance sheet, the company holds $13.16 million in cash and has $0 in debt, creating a capital position that is conservative rather than leveraged, though the cash burn rate is significant relative to total assets. The current ratio is 2.39, suggesting that the company maintains more than twice the liquid assets necessary to cover its short-term liabilities, providing a buffer against immediate liquidity pressures. Return on Equity is reported at -553.7% and Return on Assets at -120.4%, metrics that demonstrate management is currently generating negative returns on the capital base as the company invests heavily in growth rather than profitability.
估值评估
The trailing twelve-month P/E ratio is N/A due to the lack of earnings, while the forward P/E is listed as -1.88, a metric that is technically inverted and implies that traditional earnings-based valuation models are not applicable to this clinical-stage asset. The price-to-book ratio stands at 5.54, indicating that the market values the company at a premium of 5.54 times its net asset value, a valuation multiple often seen in biotech firms where future pipeline value exceeds current book value. The price-to-sales ratio and EV/EBITDA are both N/A, suggesting that sales-based or earnings-based alternative valuation metrics cannot be meaningfully applied given the absence of commercial revenue and EBITDA data. Regarding trading range, the 52-week high is $11.99 and the 52-week low is $1.77, meaning the stock price has experienced extreme volatility within this specific band over the last year. The beta value is N/A, which implies that there is insufficient historical data relative to the broader market to calculate a standard measure of price volatility, a common characteristic for smaller market capitalization stocks with limited trading history.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are both N/A, reflecting the fact that the company has not yet reached a stage of recurring commercial sales where growth rates can be calculated. Since the company does not pay a dividend, the dividend yield and payout ratio are N/A and 0.0% respectively, indicating that the firm retains all available capital to reinvest into clinical trials and product development rather than distributing income to shareholders. The absence of a dividend policy aligns with the strategic imperative for clinical-stage biotechnology companies to prioritize capital allocation toward advancing their lead product candidates through regulatory approval processes. Consequently, the overall growth and income profile for Actuate Therapeutics is characterized by a reliance on non-operating income or capital raises to fund operations, with no current stream of commercial growth or dividend income available to investors at this stage of the company's lifecycle.